5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase.
5-FU
DPD
UC-UUT
tegafur-uracil
tegafur/gimeracil/oteracil
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
11
10
2018
accepted:
19
02
2019
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
5
4
2019
Statut:
ppublish
Résumé
Lymphovascular invasion (LVI) by urothelial carcinoma of the upper urinary tract (UC-UUT) is associated with an unfavorable prognosis. However, a high proportion of patients with UC-UUT are unable to receive the recommended doses of cisplatin-based adjuvant chemotherapy due to advanced age or renal dysfunction resulting from nephroureterectomy. Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). The aim of the present study was to investigate the efficacy of adjuvant 5-fluorouracil chemotherapy for UC-UUT with LVI, and to assess the expression of enzymes associated with 5-fluorouracil metabolism as promising biomarkers of therapy efficacy. The present study retrospectively investigated 52 cases of UC-UUT. Following nephroureterectomy, tegafur-uracil was administered to 15 out of 30 patients with LVI who were not eligible for cisplatin-based adjuvant chemotherapy. Levels of
Identifiants
pubmed: 30944635
doi: 10.3892/ol.2019.10086
pii: OL-0-0-10086
pmc: PMC6444440
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4429-4436Références
Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):112-5
pubmed: 10442377
Eur J Cancer. 1999 May;35(5):738-43
pubmed: 10505034
Eur J Cancer. 2001 Mar;37(5):569-75
pubmed: 11290431
Cancer. 2001 Aug 1;92(3):510-8
pubmed: 11505394
Eur J Cancer. 2002 Feb;38(3):349-58
pubmed: 11818199
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Langenbecks Arch Surg. 2002 Mar;386(8):575-81
pubmed: 11914933
Eur J Cancer. 2002 Jun;38(9):1271-7
pubmed: 12044515
Cancer. 2004 Feb 15;100(4):723-31
pubmed: 14770427
Pharmacogenomics J. 2005;5(4):226-43
pubmed: 16041392
J Clin Oncol. 2005 Aug 1;23(22):4999-5006
pubmed: 16051951
J Urol. 2005 Dec;174(6):2120-3; discussion 2124
pubmed: 16280740
Jpn J Clin Oncol. 2006 Apr;36(4):237-44
pubmed: 16675478
Br J Cancer. 2007 Apr 23;96(8):1170-7
pubmed: 17375049
J Clin Oncol. 2009 Feb 1;27(4):612-8
pubmed: 19075275
J Thorac Oncol. 2009 Dec;4(12):1511-6
pubmed: 19875974
Int J Clin Oncol. 2010 Aug;15(4):369-75
pubmed: 20340038
BMC Cancer. 2010 Apr 28;10:164
pubmed: 20426825
Cancer. 2010 Jun 15;116(12):2967-73
pubmed: 20564402
Eur Urol. 2010 Oct;58(4):581-7
pubmed: 20619530
BMC Cancer. 2012 Sep 22;12:420
pubmed: 22998564
BJU Int. 2013 Jul;112(2):E28-34
pubmed: 23795795
J Urol. 2014 Apr;191(4):932-6
pubmed: 24211599
Curr Urol. 2012 May;6(1):27-32
pubmed: 24917706
Int J Urol. 2015 Nov;22(11):1006-12
pubmed: 26153093
Int Braz J Urol. 2015 Nov-Dec;41(6):1067-79
pubmed: 26742963
Gastric Cancer. 2017 Mar;20(2):263-273
pubmed: 26884344
Mol Clin Oncol. 2017 Jul;7(1):15-23
pubmed: 28685068
Cancer. 1993 Mar 1;71(5):1842-5
pubmed: 8448746
Clin Cancer Res. 1998 Sep;4(9):2085-8
pubmed: 9748123
Urology. 1998 Oct;52(4):594-601
pubmed: 9763077